Últimas noticias sobre iBio (NASDAQ:IBIO) Bolsa

iBio

iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.

iBio Inc

Chardan Capital analyst Keay Nakae maintains iBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>) with a Buy and maintains $5 price target.

News

Price Target

Analyst Ratings

IBIO

Chardan Capital Maintains Buy on iBio, Maintains $5 Price Target

<h3>Gainers</h3>
<ul>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) stock moved upwards by 106.2% to $0.95 during Monday's pre-market session. The company's market cap stands at $5.7 million. </li>
<li>INVO Fertility (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVF#NASDAQ">IVF</a>) stock rose 22.22% to $2.2. The company's market cap stands at $10.8 million. </li>
<li>Firefly Neuroscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIFF#NASDAQ">AIFF</a>) shares rose 15.63% to $3.78. The company's market cap stands at $30.5 million. </li>
<li>BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) shares rose 14.89% to $10.26. The market value of their outstanding shares is at $2.1 billion. As per the news, the Q1 earnings report came out today. </li>
<li>iBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>) stock moved upwards by 14.88% to $1.16. The company's market cap stands at $11.4 million. The company's, Q3 earnings came out yesterday. </li>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) shares rose 11.31% to $6.79. The market value of their outstanding shares is at $139.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Pliant Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) stock declined by 89.9% to $1.7 during Monday's pre-market session. The company's market cap stands at $104.5 million. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock decreased by 21.53% to $0.59. The market value of their outstanding shares is at $6.7 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) shares fell 21.32% to $0.4. The market value of their outstanding shares is at $9.4 million. </li>
<li>Nexalin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) shares fell 16.21% to $1.5. The market value of their outstanding shares is at $19.9 million. </li>
<li>ModivCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) stock decreased by 14.39% to $1.25. The market value of their outstanding shares is at $17.9 million. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) shares declined by 14.09% to $0.43. The company's market cap stands at $2.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AIFF

APVO

BCRX

MODV

NCNA

PLRX

QNRX

RNAZ

12 Health Care Stocks Moving In Monday's Pre-Market Session

<ul>
<li>Activin E antibody demonstrates significant decrease in fat in obese mice by reducing visceral fat depots, which are strongly linked to increased risk of cardiovascular and metabolic diseases, resulting in a 26% reduction in fat mass with no loss in muscle</li>
<li>Strong synergistic effect on fat mass (77% reduction) was observed when the Activin E antibody was combined with a GLP-1 receptor agonist, resulting in total weight loss of 35.3%, 7.5% greater than GLP-1 alone &nbsp;</li>
</ul>
SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- iBio, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>), an AI-driven innovator of precision antibody therapies, today announced new promising preclinical data for its <a href="https://www.globenewswire.com/Tracker?data=jh7cCF2OKqZ5xu_O7XfSQMo5p4tDPzgs2pnT-iqyweEskYWjs3pWmGeg0UU9p-1sLO-OAMW4fUD5GJH3wlT1lS3ZmKFHypTyXv9k6JFLEBYJ1Fd41VG46I42nxZN6DKykZOR4IQiEdJO-XqZJqAh9eoPBGE_pzhRP0yG5YTDrGUrhEOqKQcSFu-yWO61sjwsdGYlfPPtX0sotkFG3tD5epWenlMuClx2K8jl3ZeJIbnNhgdEe_Di_I4e77VLcz-QgfIBhT1Lsj3IOKGO_hw0tA==">first-in-class Activin E antibody unveiled in January</a>. Data from the recently completed 4-week study in diet-induced obese mice show a 26% reduction in fat mass following treatment with the Activin E antibody, with muscle mass fully preserved. These findings highlight a significant fat loss can be achieved without the double-digit weight reductions typically required by other obesity drugs.
GLP-1 receptor agonists are effective at promoting weight loss. However, they can also reduce lean body mass, including muscle, which may limit some of the intended health benefits. In contrast, fat-specific weight loss is considered a higher-quality form of weight loss. It reduces fat—linked to lower risk of heart and metabolic diseases—while preserving muscle, which helps maintain strength, supports a healthy metabolism, and may prevent or reduce weight regain over time.

Biotech

General

iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss And Shows Synergy With GLP-1s In Preclinical Model; Strong Synergistic Effect On Fat Mass (77% Reduction) Was Observed When The Activin E Antibody Was Combined With A GLP-1 Receptor Agonist, Resulting In Total Weight Loss Of 35.3%, 7.5% Greater Than GLP-1 Alone

iBio (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#AMEX">IBIO</a>) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.34) by 44.12 percent. This is a 30.99 percent increase over losses of $(0.71) per share from the same period last year.

Earnings

Earnings Misses

iBio Q3 EPS $(0.49) Misses $(0.34) Estimate

iBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>) ("iBio" or the "Company"), an AI-driven innovator of precision antibody therapies, announces today announced that it has entered into an agreement with institutional investors that are existing holders of warrants to purchase shares of common stock of the Company for cash (the "Existing Warrants"), wherein the investors agreed to exercise the Existing Warrants to purchase 5,626,685 shares of common stock at a reduced exercise price of $1.11 per share, resulting in gross proceeds of approximately $6.2 million, before deducting advisory fees and certain other expenses. The Company intends to use the net proceeds for working capital and other general corporate purposes.

Institutional Investors Exercise iBio Warrants At Reduced Exercise Price Of $1.11/Shr Resulting In Gross Proceeds Of About $6.2M

<h3>Gainers</h3>
<ul>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) shares rose 50.4% to $0.02 during Tuesday's regular session. </li>
<li>Kala Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALA#NASDAQ">KALA</a>) stock rose 39.13% to $4.97. The market value of their outstanding shares is at $30.2 million. </li>
<li>ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) shares increased by 33.48% to $5.74. The market value of their outstanding shares is at $3.0 million. </li>
<li>LifeMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFMD#NASDAQ">LFMD</a>) shares moved upwards by 32.78% to $8.1. The market value of their outstanding shares is at $361.1 million. </li>
<li>iBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>) shares increased by 27.14% to $1.33. The market value of their outstanding shares is at $13.1 million. </li>
<li>Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) stock rose 26.12% to $35.92. The company's market cap stands at $8.0 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) stock decreased by 71.0% to $0.02 during Tuesday's regular session. </li>
<li>Zhengye Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYBT#NASDAQ">ZYBT</a>) shares decreased by 34.63% to $9.25. The company's market cap stands at $438.3 million. </li>
<li>NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) stock declined by 31.9% to $6.79. The market value of their outstanding shares is at $872.2 million. The company's, Q1 earnings came out today. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) stock decreased by 25.2% to $4.84. The company's market cap stands at $2.9 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) stock declined by 23.37% to $4.56. The company's market cap stands at $69.4 million. </li>
<li>Relmada Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLMD#NASDAQ">RLMD</a>) stock fell 15.99% to $0.3. The company's market cap stands at $9.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Hims & Hers Health, Inc. Class A Common Stock

HIMS

KALA

LFMD

LGMK

NDRA

PTPI

RLMD

TIVC

ZYBT

12 Health Care Stocks Moving In Tuesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) shares increased by 34.5% to $0.01 during Monday's regular session. </li>
<li>CG Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGON#NASDAQ">CGON</a>) shares moved upwards by 32.81% to $29.71. The market value of their outstanding shares is at $2.2 billion. </li>
<li>Zhengye Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYBT#NASDAQ">ZYBT</a>) stock rose 32.18% to $13.8. The company's market cap stands at $654.0 million. </li>
<li>iBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>) shares moved upwards by 30.56% to $1.2. The company's market cap stands at $11.8 million. </li>
<li>Gelteq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GELS#NASDAQ">GELS</a>) shares increased by 24.21% to $2.36. The company's market cap stands at $22.2 million. </li>
<li>Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) shares moved upwards by 24.0% to $1.21. The company's market cap stands at $6.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Spruce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRB#NASDAQ">SPRB</a>) shares fell 26.2% to $0.1 during Monday's regular session. The company's market cap stands at $3.9 million. </li>
<li>SILO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) stock fell 22.6% to $0.89. The company's market cap stands at $3.9 million. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) shares decreased by 20.8% to $3.96. The market value of their outstanding shares is at $102.9 million. </li>
<li>Abpro Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABP#NASDAQ">ABP</a>) stock fell 18.94% to $0.26. The market value of their outstanding shares is at $13.4 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares decreased by 18.74% to $0.15. The company's market cap stands at $6.7 million. </li>
<li>Protara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TARA#NASDAQ">TARA</a>) stock declined by 18.52% to $3.52. The company's market cap stands at $129.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BCLI

CGON

GELS

HCTI

SILO

SNTI

SPRB

TARA

12 Health Care Stocks Moving In Monday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Gelteq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GELS#NASDAQ">GELS</a>) stock moved upwards by 236.7% to $3.03 during Tuesday's regular session. The company's market cap stands at $28.5 million. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) stock increased by 138.27% to $2.43. The market value of their outstanding shares is at $33.4 million. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) stock increased by 121.42% to $7.75. The company's market cap stands at $4.7 million. </li>
<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) stock moved upwards by 58.85% to $14.44. The company's market cap stands at $23.7 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) shares increased by 30.59% to $0.84. The company's market cap stands at $4.9 million. </li>
<li>Akso Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHG#NASDAQ">AHG</a>) stock moved upwards by 28.97% to $1.38. The market value of their outstanding shares is at $550.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Vincerx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINC#NASDAQ">VINC</a>) shares decreased by 28.0% to $0.1 during Tuesday's regular session. </li>
<li>iBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>) stock fell 17.91% to $0.7. The company's market cap stands at $6.8 million. </li>
<li>Scilex Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCLX#NASDAQ">SCLX</a>) shares fell 16.39% to $3.93. The company's market cap stands at $20.5 million. </li>
<li>Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) shares fell 13.49% to $4.17. The company's market cap stands at $186.7 million. </li>
<li>Adagio Medical Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADGM#NASDAQ">ADGM</a>) stock declined by 11.56% to $1.06. The company's market cap stands at $16.4 million. </li>
<li>Kala Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALA#NASDAQ">KALA</a>) shares decreased by 10.64% to $2.94. The company's market cap stands at $17.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADGM

PRTG

PSTV

SCLX

SXTC

VINC

YMAB

<a href="https://www.globenewswire.com/Tracker?data=yfZ2eSHDjFlismVQ22s7M9ahGIsxc_c3JjmLemcisJobsa7peXhySiz3DFrXLtooq_g_f-kPedb-852zUon7n4qfGS2joB0T27fsCeHHKYYtw-aQJo35C-X1FD-BX-FCvZKlVgEPP51WycSwzCraxE1fTU-LuVNL9f5gb1jMK_KlfH7jsUwMxcGVsDdKfbInO7SPuLXztF4TCyZm3-Hv7-SU6ahOnQyaTE3rbNNQK5z7ZGUaeN9zQncx-ehsALJgmYNDdESneNf5OfsvcU8U-V3wN1JkJaKsPN9NYHEEpn0P3cC8zJB6CXCLVVSVPrXhKTAQWCCT41fQ4Y75_sB5364FIFW_kWoJF0Nxt6gjl-aTyM8QDlzBZ4lIyPwMj960SXfgwL2CMfNxSm9lWOuz5Fm8GCIYi29ve90WTSwBYLs=">Bio, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>), an AI-driven innovator of precision antibody therapies, today announced a licensing agreement with AstralBio Inc. for a preclinical first-in-class antibody targeting <a href="https://www.globenewswire.com/Tracker?data=2Ap9Z7U3HayJzgEw3tx13uO0r3yrphLjM4Fi4nyTVJEqF6LUdjUxq6W1UgaoCpDR75nPmjcAH8gb-akQ4d42b5HGP6n3FFxu1Qkm-WC59rkA-ng-syij9rLfgJySEkoIxhNkLegX__IsPydEZJE4NlyR2eXOPVvZOiUgxwB7AGnX2GiO65WX8MFHRXhdOEHFA3Dzvy-sBaE9Sn_-1m20PCjJDQaFHfLkGEPIZMSXjt3YHpCw2DMICI9FQYGVK_G907DW4sbDJM7sE6WUQhC2jzuivj8nFSylTCkdzLzgt45ZRPJL8w-PMf4g7QEEJ7CE">Activin E, which was discovered using iBio's patented Machine-Learning Antibody Engine</a>. Activin E is a promising novel therapeutic target whose inhibition is believed to induce fat-selective weight loss and offer protection against obesity and cardiometabolic disease. iBio plans to rapidly advance testing of the antibody in more complex models following preclinical studies that demonstrated strong antibody binding, inhibition of Activin E signaling and fat-specific weight loss in an obese rodent animal model.
The in-licensed antibody represents what iBio believes to be the first functional inhibitor of Activin E, a challenging, yet genetically validated therapeutic target playing a key role in regulating energy balance and fat distribution. Inhibiting Activin E-mediated signaling could offer a novel therapeutic strategy to reduce internal abdominal fat while preserving muscle mass—potentially reversing obesity, preventing diabetes, and improving overall cardiometabolic health. As one of several cellular components involved in cardiometabolic regulation, Activin E, along with amylin, GLP-1 and others, are part of a broader network of signaling pathways that have the potential to be targeted simultaneously to yield synergistic benefits for patients.
Using its proprietary Machine Learning Antibody Engine and advanced epitope engineering technology, iBio designed engineered epitopes representing five key regions of the Activin E protein. This approach led to the successful development of a molecule that fully blocks Activin E-mediated signaling and inhibits its function across multiple in vitro models. In vivo proof-of-concept was established in a rodent model of obesity, where the antibody induced fat-selective weight loss as a monotherapy and showed synergistic weight loss when added to a GLP-1 receptor agonist in <a href="https://www.globenewswire.com/Tracker?data=IC6CnWZUDTXt2k2kQcI4UJS1sr27bCIdXB-9lKCH8hUbHT9eSX6RDqG0dYhVJoP0JKTOGoC1X4gdoMxNyQ8ynAHTRfFgqQKESrJ9tavPegKHu6w_bc9eAAY8NIS3PlJpiOr4wMu1FUImPpFwVI8vsHJnGXMEZTaiaFlygE1a550MScR6WC_Is1iLv-scMHL1eGjJQKeszBIQMEDM0twrdJ-WOs-WEx9vGSAr96a0bJg=">recently published data</a> by iBio. iBio plans to present additional preclinical data of its antibody targeting Activin E at the International BMP Conference, taking place in Philadelphia, PA, from May 2–6.
"Our decision to license this Activin E-targeting functional antibody, a potentially first-in-class molecule, at this early stage reflects our firm belief in Activin E as a promising therapeutic target and our confidence in building upon the strong preclinical data we recently published," said Martin Brenner, Ph.D., DVM, iBio's Chief Executive Officer and Chief Scientific Officer. "This antibody represents a strategic expansion of our pipeline in cardiometabolic diseases and obesity and a significant step toward clinical development of a medication that can potentially offer meaningful benefits to patients."

iBio, Announces A Licensing Agreement With Astralbio For A Preclinical First-In-Class Antibody Targeting Activin E

<h3>Gainers</h3>
<ul>
<li>Gelteq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GELS#NASDAQ">GELS</a>) shares increased by 371.1% to $4.24 during Tuesday's pre-market session. The market value of their outstanding shares is at $40.0 million. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) stock increased by 59.0% to $0.06. The company's market cap stands at $10.5 million. </li>
<li>Orchestra BioMed Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBIO#NASDAQ">OBIO</a>) shares rose 28.52% to $3.65. The company's market cap stands at $138.0 million. </li>
<li>Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) stock rose 20.99% to $0.28. The market value of their outstanding shares is at $7.2 million. </li>
<li>iBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>) stock rose 20.31% to $1.02. The market value of their outstanding shares is at $10.0 million. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) shares increased by 16.66% to $1.19. The company's market cap stands at $16.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Vincerx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINC#NASDAQ">VINC</a>) stock declined by 22.9% to $0.1 during Tuesday's pre-market session. </li>
<li>Sionna Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SION#NASDAQ">SION</a>) stock fell 17.53% to $9.32. The company's market cap stands at $409.9 million. </li>
<li>Outset Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OM#NASDAQ">OM</a>) shares fell 16.74% to $8.31. The market value of their outstanding shares is at $147.2 million. </li>
<li>Tyra Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TYRA#NASDAQ">TYRA</a>) stock decreased by 16.01% to $7.61. The market value of their outstanding shares is at $404.0 million. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) stock fell 13.96% to $0.14. The market value of their outstanding shares is at $3.8 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) stock declined by 12.08% to $3.64. The company's market cap stands at $55.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

KLTO

Orchestra BioMed Holdings, Inc. - Ordinary Shares

OBIO

OCEA

SION

TYRA

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) shares rose 126.3% to $7.99 during Monday's regular session. The company's market cap stands at $4.4 million. </li>
<li>Artiva Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARTV#NASDAQ">ARTV</a>) shares moved upwards by 35.04% to $3.29. The market value of their outstanding shares is at $80.2 million. </li>
<li>Shuttle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) shares moved upwards by 34.43% to $0.52. The company's market cap stands at $3.2 million. </li>
<li>Shattuck Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STTK#NASDAQ">STTK</a>) shares increased by 32.3% to $0.97. The company's market cap stands at $46.4 million. </li>
<li>Agape ATP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) stock rose 30.32% to $1.59. The market value of their outstanding shares is at $6.3 million. </li>
<li>Sutro Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRO#NASDAQ">STRO</a>) stock moved upwards by 28.13% to $0.69. The company's market cap stands at $58.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>iBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>) shares fell 43.0% to $1.84 during Monday's regular session. The market value of their outstanding shares is at $18.1 million. </li>
<li>China Pharma Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CPHI#AMEX">CPHI</a>) stock decreased by 39.91% to $0.13. The market value of their outstanding shares is at $2.5 million. </li>
<li>Lexeo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXEO#NASDAQ">LXEO</a>) stock fell 29.32% to $1.65. The company's market cap stands at $54.7 million. </li>
<li>Alumis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) stock decreased by 23.49% to $7.69. The company's market cap stands at $418.3 million. </li>
<li>Aditxt (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) stock fell 23.16% to $3.63. The market value of their outstanding shares is at $3.7 million. </li>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares decreased by 22.87% to $0.02. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADTX

ALMS

ARTV

ATPC

BJDX

CPHI

LXEO

SHPH

STRO

STSS

STTK

<ul>
<li>Non-human primate pharmacokinetics data suggests IBIO-600, a potentially best-in-class long-acting anti-myostatin antibody, could have a human half-life as long as 130 days.</li>
<li>Additional interim in vivo data for a first-in-class Activin E antibody shows muscle sparing weight loss alone and in combination with a GLP-1 receptor agonist.</li>
<li>iBio remains on track to submit a regulatory submission for IBIO-600 in Q1 2026.</li>
</ul>

Health Care

iBio's Non-GLP Non-human Primate Pharmacokinetics Study Suggests IBIO-600, Anti-myostatin Antibody Designed For Subcutaneous Administration, Could Provide A Significantly Extended Half-life In Humans And A Weight Loss Treatment Option While Preserving And Promoting Muscle Growth

CORRECTION: Impact BioMedical Ticker Is "IBO"

iBio To Begin Trading On Nasdaq On March 4, 2025 Under "IBIO"

iBio (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#AMEX">IBIO</a>) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.32) by 50 percent. This is a 80.17 percent increase over losses of $(2.42) per share from the same period last year. The company reported $200.00 thousand in sales this quarter.

iBio Q2 EPS $(0.48) Misses $(0.32) Estimate, Sales $200.00K

iBio plans to rapidly advance testing of this molecule and additional candidates in more complex and disease relevant models.

iBio In Collaboration With AstralBio, Announced The Development Of An Antibody That Inhibits The Function Of Activin E, Therapeutic Target For Cardiometabolic Disorders And Obesity Using iBio's Machine-learning Antibody Engine

On Thursday, iBio, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NYSE">IBIO</a>) expanded its cardiometabolic and obesity treatment development program by in-licensing a potentially long-acting anti-myostatin antibody from AstralBio, Inc.
In March, iBio collaborated with&nbsp;AstralBio to discover, engineer, and develop antibodies to treat obesity and&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37959621/micro-cap-stock-ibio-doubles-on-wednesday-heres-why" rel="noreferrer noopener">other cardiometabolic conditions</a>.
The antibody, now named IBIO-600, was identified by AstralBio using iBio&#8217;s proprietary technology stack. It was designed for subcutaneous administration and has the potential for <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g42761297/ibio-expands-cardiometabolic-and-obesity-program-with-anti-myostatin-antibody-discovered-using-its" rel="noreferrer noopener">an extended half-life</a>.
AstralBio will receive an upfront payment of $750,000, which iBio has paid by issuing its common stock to AstralBio.
In addition, AstralBio will be eligible for development and commercialization milestone payments totaling up to $28 million.
If iBio sublicenses the licensed product, AstralBio will receive low to mid-single-digit sublicense fees on the proceeds of the sublicense fees.
iBio is solely responsible for the research and development, manufacturing, and commercialization activities of the licensed product.
In parallel, iBio initiated a bispecific antibody program targeting myostatin/activin A to treat obesity and cardiometabolic disorders, leveraging its proprietary Drug Discovery Platform and the technology of IBIO-600.
The myostatin licensing agreement and planned myostatin/activin A bispecific antibody program follows a drug discovery and development collaboration between iBio and AstralBio initiated less than a year ago.
iBio plans to enter into clinical investigation in obesity and cardiometabolic disorders in 2026.
In preclinical studies, IBIO-600 exhibits potent inhibition of myostatin in human muscle cell precursors, effectively blocking its inhibitory effects on muscle growth.
The company adds that IBIO-600 has been engineered to bind to the FcRn receptor with more than 10-fold higher affinity than normal IgG, supporting the potential for reduced dosing frequency.
The molecule has been advanced into non-cGMP&nbsp;in vivo studies in rodents and non-human primates, with the first data read-outs expected in early 2025.
iBio plans to use the machine-learning and epitope-steering capabilities of the Stable HU antibody optimizer with advanced mammalian display to design and produce additional multispecific antibodies targeting TGF-beta superfamily, including Myostatin and Activin A in in-vitro studies.
Price Action: At last check on Thursday, IBIO stock was up 2.04% at $2.50 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/01/42764490/us-employer-health-costs-to-rise-in-2025-fueled-by-weight-loss-report">US Employer Health Costs To Rise In 2025 Fueled By Weight Loss: Report</a></li>
</ul>
Photo via Shutterstock

Contracts

Nano-Cap iBio Expands Obesity Program With New Antibody Using In-Licensed Platform

<a href="https://www.globenewswire.com/Tracker?data=HZylVBKL9vtxA17iySuvrrc1wp4Rcx0tltN78FWTAZ1BeixIwg73Ye6eUEMmQfWgdAnz37k-BL0SwZd3n1F0Cg==">iBio, Inc</a>. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, today announced the expansion of its cardiometabolic and obesity treatment development program by in-licensing a potentially best-in-class long-acting anti-myostatin antibody from AstralBio, Inc. The antibody, now named IBIO-600, was identified by AstralBio using iBio's proprietary technology stack and was designed for subcutaneous administration with the potential for an extended half-life.
Pursuant to the agreement, AstralBio will receive an upfront payment of $750,000, which iBio has paid by issuing its common stock to AstralBio. In addition, AstralBio will be eligible for development and commercialization milestone payments totaling up to $28 million. If iBio sublicenses the licensed product, AstralBio will receive low to mid-single-digit sublicense fees on the proceeds of the sublicense fees. iBio is solely responsible for the research and development, manufacturing and commercialization activities of the licensed product.
In parallel, iBio initiated a bispecific antibody program targeting myostatin/activin A to treat obesity and cardiometabolic disorders, leveraging its proprietary Drug Discovery Platform as well as the technology of IBIO-600. The myostatin licensing agreement and planned myostatin/activin A bispecific antibody program follows a drug discovery and development collaboration between iBio and AstralBio initiated less than a year ago. iBio plans to enter into clinical investigation in obesity and cardiometabolic disorders in 2026.

iBio Expands Obesity Program with $750K Upfront Payment and $28M AstralBio Partnership

LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on iBio (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#AMEX">IBIO</a>) with a Buy rating and announces Price Target of $6.

Initiation

LUCID CAPITAL MARKETS Initiates Coverage On iBio with Buy Rating, Announces Price Target of $6

iBio (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#AMEX">IBIO</a>) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.48) by 4.17 percent. This is a 89.15 percent increase over losses of $(4.24) per share from the same period last year.

Earnings Beats

iBio Q1 EPS $(0.46) Beats $(0.48) Estimate

Press Releases

iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio

iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio

Financing

iBio Announces New Investments from Board Members and Officers

iBio Reports Fiscal Second Quarter 2025 Financial Results

Markets

iBio to Begin Trading on the Nasdaq Stock Exchange

iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio

iBio Raises $6.2 Million Through Warrant Inducement Transaction

iBio Reports Fiscal Third Quarter 2025 Financial Results

iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

Comments

iBio

Noticias

Últimas noticias sobre iBio (NASDAQ:IBIO) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL